Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib

Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells

(2014) Chuan-Ming Xie et al.   Autophagy

Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer

(2014) Dena A. Jerjees et al.   BREAST CANCER RESEARCH AND TREATMENT

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)

(2014) M. Takada et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The essential role of TNIK gene amplification in gastric cancer growth

(2014) D-H Yu et al.   Oncogenesis

RON confers lapatinib resistance in HER2-positive breast cancer cells

(2013) Quanren Wang et al.   CANCER LETTERS

Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib

(2013) Antonella De Luca et al.   CELL CYCLE

Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib

(2013) Xingmei Zhu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

(2013) André Robidoux et al.   LANCET ONCOLOGY

Enhanced PI3K p110  Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110 -Selective PI3K Inhibitor

(2013) S. W. Brady et al.   MOLECULAR CANCER THERAPEUTICS

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

(2013) X Sui et al.   Cell Death & Disease

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer

(2013) L-Y Huw et al.   Oncogenesis

Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence

(2012) Antonis Valachis et al.   BREAST CANCER RESEARCH AND TREATMENT

miRNA-130a Targets ATG2B and DICER1 to Inhibit Autophagy and Trigger Killing of Chronic Lymphocytic Leukemia Cells

(2012) V. Kovaleva et al.   CANCER RESEARCH

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

(2012) C.-T. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Selective autophagy degrades DICER and AGO2 and regulates miRNA activity

(2012) Derrick Gibbings et al.   NATURE CELL BIOLOGY

Structure of the human ATG12~ATG5 conjugate required for LC3 lipidation in autophagy

(2012) Chinatsu Otomo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Seeing is believing: The impact of electron microscopy on autophagy research

(2011) Eeva-Liisa Eskelinen et al.   Autophagy

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH

HER-2 Signaling and Inhibition in Breast Cancer

(2009) B. Browne et al.   CURRENT CANCER DRUG TARGETS

Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization

(2008) M. A. Qadir et al.   BREAST CANCER RESEARCH AND TREATMENT

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY